These innovative molecules represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose https://maezcvd402243.is-blog.com/45967785/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide